Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sclerostin antibody enhances implant osseointegration in bone with Col1a1 mutation.

Bone - 1 Sept 2024

Sung Hsiao H, Kwon Hanna H, Stephan Chris, Reynolds Skylar M, Dai Zongrui, Van der Kraan Peter M, Caird Michelle S, Blaney Davidson Esmeralda N, Kozloff Kenneth M

Abstract excerpt

We evaluated the potential of sclerostin antibody (SclAb) therapy to enhance osseointegration of dental and orthopaedic implants in a mouse model (Brtl/+) mimicking moderate to severe Osteogenesis Imperfecta (OI). To address the challenges in achieving stable implant integration in compromised bone conditions, our aim was to determine the effectiveness of sclerostin antibody (SclAb) at improving bone-to-implant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adaptor Proteins, Signal Transducing
Share to Antibodies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bone and Bones

Share to Collagen Type I

Share to Dental Implants

Share to Intercellular Signaling Peptides and Proteins

Share to X-Ray Microtomography

Source

Open in PubMed Open full text

Identifiers

PMID: 38876270
DOI: 10.1016/j.bone.2024.117167
PMCID: PMC11243590

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sclerostin antibody enhances implant osseointegration in bone with Col1a1 mutation.PMID 38876270Read ↗

Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim Mice.Semantic proximity Read ↗

Effect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age.Semantic proximity Read ↗

Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap–/– Mice, a Model of Recessive Osteogenesis ImperfectaSemantic proximity Read ↗

Sclerostin and DKK1 Inhibition Preserves and Augments Alveolar Bone Volume and Architecture in Rats with Alveolar Bone Loss.Semantic proximity Read ↗

Combination Treatment with Sclerostin and Dkk1 Antibodies Synergizes with Tibial Loading to Stimulate Bone Formation in Aged MiceSemantic proximity Read ↗

Sclerostin antibody treatment rescues the osteopenic bone phenotype of TGFβ inducible early gene-1 knockout female mice.Semantic proximity Read ↗

Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.Semantic proximity Read ↗

Does Sclerostin Depletion Stimulate Fracture Healing in a Mouse Model?Semantic proximity Read ↗

Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats.Semantic proximity Read ↗

The Role of Sclerostin in Bone DiseasesSemantic proximity Read ↗

Early intermittent low-dose sclerostin antibody treatment promotes surface bone formation and reduces bone loss, but also decreases osteocyte apoptosis and mechanotransduction in ovariectomized rats: a pilot studySemantic proximity Read ↗

SclerostinSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.